Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Pieter R. Cullis, PhD, FRSC, FRS, OBC, OC, Director, Nanomedicines Research Group, Professor, Department of Biochemistry and Molecular Biology, University of British Columbia. Dr. Cullis and co-workers have been responsible for fundamental advances in the development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines. This work has contributed to five drugs that have received clinical approval by the FDA, the European EMA and Health Canada. Dr. Cullis has also co-founded more than 10 biotechnology companies that now employ over 500 people, has published over 400 scientific articles (h index 140) and is an inventor on over 100 patents. He has also co-founded and been Founding Scientific Director of two National Centre of Excellence networks, the Centre for Drug Research and Development (now AdMare) in 2004 and the NanoMedicines Innovation Network in 2019. These not-for-profit networks are aimed at translating basic research in the life sciences into commercially viable products and have given rise to numerous start-up companies. Dr. Cullis also has a strong interest in personalized medicine, having published a book entitled “The Personalized Medicine Revolution: How Diagnosing and Treating Disease Are About to Change Forever” in 2015.

Two drugs enabled by LNP delivery systems devised by Dr. Cullis, members of his UBC laboratory and colleagues in the companies he has co-founded deserve special emphasis. The first is Onpattro which was approved by the US FDA in August 2018 to treat the previously fatal hereditary condition transthyretin-induced amyloidosis (hATTR). Onpattro is the first RNAi drug to receive regulatory approval. The second is Comirnaty, the COVID-19 mRNA vaccine developed by Pfizer/BioNTech that has received regulatory approval in many jurisdictions including Canada, the USA, the UK and Europe. Comirnaty has played a major role in containing the global Covid-19 pandemic with approximately 6B doses administered worldwide in 2021 and 2022.

Dr. Cullis has received many awards including the Order of Canada in 2021, the VinFuture Prize (Vietnam), the Prince Mahidol Award (Thailand), the Gairdner International Award (Canada) and the Tang Prize (Taiwan) in 2022 and the Harvey Prize (Israel) and the Killam Prize (Canada) in 2023. He was made a Fellow of the Royal Society (London) in 2023 and elected to the Canadian Medical Hall of Fame in 2024.

Diane Finegood is a Professor and Fellow in the Morris J. Wosk Centre for Dialogue at Simon Fraser University where she teaches in the Semester in Dialogue. Her career has spanned a broad range of disciplines and leadership roles. She served as President & CEO of the Michael Smith Foundation for Health Research, Executive Director of the Canadian Health Services and Policy Research Alliance and inaugural Scientific Director of the Canadian Institutes of Health Research, Institute of Nutrition, Metabolism and Diabetes. Diane is internationally recognized with scholarly work in a range of disciplines including pathogenesis of type 1 and type 2 diabetes, application of mathematical modeling to physiological systems, cross sector partnership, knowledge mobilization, systems thinking and complex adaptive systems.

Dr. Martin Dawes is a world expert in primary care who combines research and clinical practice with over 30 years of experience. Following the completion of his PhD, he helped develop a Masters program in Evidence Based Health Care. He has directed the UK Centre for Evidence-Based Medicine in Oxford and was the head of family practice at McGill University and the University of British Columbia. He is the co-founder and scientific director  of GenXys, a medication decision support software company.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Dr. Lee Hood is a world-renowned scientist and has interest in technology development, cross-disciplinary biology for pioneering strategies and technologies, systems biology and data-driven Health. Dr. Leroy Hood co-founded the Institute for Systems Biology (ISB) in 2000, served as president from 2000-2017, and continues as a Professor. He is also Professor and Chief Innovation Officer at the Buck Institute for Research in Aging and CEO of the nonprofit he founded in 2021, Phenome Health, which drives data-driven health.

He received his MD from Johns Hopkins University School of Medicine (1963) and his PhD in biochemistry from Caltech (1967). Dr. Hood was a Senior Investigator for the National Cancer Institute (1967-1970). Dr. Hood was a faculty member at Caltech from 1970-1992, serving for 10 years as the Chair of Biology. During this period, he and his colleagues developed four sequencer and synthesizer instruments for DNA and proteins that paved the way for the Human Genome Project’s successful sequencing of the human genome. He and his students also deciphered many of the complex mechanisms of antibody diversification. In 1992, Dr. Hood founded and chaired the the first cross-disciplinary Department of Molecular Biotechnology at the University of Washington. In 2013 he pioneered data-driven health (genome/phenome analyses of individuals) with the year-long 100 person project and then the co-founding of Arivale with its 4 year recruitment of 5000 patients. He is currently pioneering data-driven health and recruiting partners to join him in fundamentally changing healthcare to optimizing wellness, facilitating healthy aging, preventing disease. In 2025 he co-founded P4Bios a peptide drug company that plans transform the pharmaceutical industry. He is currently advocating a continuation of the Human Genome Project termed the Human Phenome Initiative to catalyze a Healthcare for individuals of Wellness and Prevention. Dr. Hood has received national and international awards including the Lasker Award (1987), the Koyto Prize (2006), the National Medical of Science (2011) and the Michael Sela Prize for Biomedicine (2025). He has co-authored text books in biochemistry, immunology, cell biology, genetics and systems biology and medicine. He has co-authored two popular books, The Code of Codes (1991) and the Age of Scientific Wellness ((2023).

Dr. Alan Rabinowitz received his medical degree from the University of Cape Town, South
Africa, completed his internal medicine and cardiology training at the University of Toronto and undertook subsequent training in interventional cardiology at St Paul’s Hospital, University of British Columbia.

He was formerly Director of the Cardiac Intensive Care Unit at St Paul’s Hospital and is currently a cardiologist and Clinical Associate Professor in the Division of Cardiology at St Paul’s Hospital, Vancouver, University of British Columbia and an associate member of the Centre for Heart Lung Innovation at St Paul’s Hospital/UBC.

He has held numerous roles in both public and private healthcare entities globally.

Stemming from his term as President of the Medical Staff Association at Providence Health Care in Vancouver, he has had various advisory positions on the New St Paul’s Hospital and Health Campus Redevelopment Project.

He is a member of the CORE of the Rural Coordination Centre of BC, which coordinates healthcare on behalf of the citizens of rural and remote British Columbia and collaborates on developing clinical solutions driven from the grassroots within a framework of holistic wellness.

Past and present roles in the realm of data driven healthcare include an advisory role to the CEO of the Royal College of Physicians and Surgeons of Canada on system change and implementation science, membership on the Canadian Cardiovascular Society AI Advisory Committee and co-authorship on manuscripts in computational biology as well as on the specifications for a data trust in Canada. He is a member of the UBC data science and health research excellence cluster and a research fellow in the School of Data Science and Computational Thinking at Stellenbosch University, South Africa.

Dr Rabinowitz has also been at the forefront of numerous entrepreneurial initiatives all aimed at harnessing exponential technologies to effect paradigm shifts on behalf of the collective, within a model of public-private partnership. He is newly the Chief Medical Officer and Director of Medical Partnerships for AIML Innovations, a Canadian company that has developed a neural network just released commercially that incorporates a foundational signal optimization engine for real-world physiological data. The initial focus for the group is on improving diagnostic yield from cardiac waveform in the clinical space and optimizing analytic yield in the context of iterative research and innovation. Thereafter, the algorithm will be applied to modalities in the cardiovascular space other than waveform such as cardiac ultrasound and imaging, and as well to the same modalities in areas other than cardiovascular, such as the neurosciences, with the ultimate goal of integrating multiple sensory inputs to contribute insight into the human form.

Dr. Lee Hood is a world-renowned scientist and has interest in technology development, cross-disciplinary biology for pioneering strategies and technologies, systems biology and data-driven Health. Dr. Leroy Hood co-founded the Institute for Systems Biology (ISB) in 2000, served as president from 2000-2017, and continues as a Professor. He is also Professor and Chief Innovation Officer at the Buck Institute for Research in Aging and CEO of the nonprofit he founded in 2021, Phenome Health, which drives data-driven health.

He received his MD from Johns Hopkins University School of Medicine (1963) and his PhD in biochemistry from Caltech (1967). Dr. Hood was a Senior Investigator for the National Cancer Institute (1967-1970). Dr. Hood was a faculty member at Caltech from 1970-1992, serving for 10 years as the Chair of Biology. During this period, he and his colleagues developed four sequencer and synthesizer instruments for DNA and proteins that paved the way for the Human Genome Project’s successful sequencing of the human genome. He and his students also deciphered many of the complex mechanisms of antibody diversification. In 1992, Dr. Hood founded and chaired the the first cross-disciplinary Department of Molecular Biotechnology at the University of Washington. In 2013 he pioneered data-driven health (genome/phenome analyses of individuals) with the year-long 100 person project and then the co-founding of Arivale with its 4 year recruitment of 5000 patients. He is currently pioneering data-driven health and recruiting partners to join him in fundamentally changing healthcare to optimizing wellness, facilitating healthy aging, preventing disease. In 2025 he co-founded P4Bios a peptide drug company that plans transform the pharmaceutical industry. He is currently advocating a continuation of the Human Genome Project termed the Human Phenome Initiative to catalyze a Healthcare for individuals of Wellness and Prevention. Dr. Hood has received national and international awards including the Lasker Award (1987), the Koyto Prize (2006), the National Medical of Science (2011) and the Michael Sela Prize for Biomedicine (2025). He has co-authored text books in biochemistry, immunology, cell biology, genetics and systems biology and medicine. He has co-authored two popular books, The Code of Codes (1991) and the Age of Scientific Wellness ((2023).

Tim Murphy is a senior healthcare executive driven by a singular purpose: to make a positive difference in the health of families, friends, and communities.

With over 30 years of leadership experience, Tim has spearheaded initiatives that modernize healthcare systems, improve outcomes, and foster innovation. As Vice President of Health at Alberta Innovates, he advanced the adoption of data, technology, and patient-centered approaches, working closely with health tech companies and system stakeholders to create the conditions for innovation to thrive.

His earlier work includes leading the Movember Foundation’s expansion into mental health as a Second Cause Beneficiary in Canada and establishing the National Pediatric Inflammatory Bowel Disease Network, both of which continue to impact lives today. Tim also helped lead Alberta’s Strategy for Patient-Oriented Research, embedding patient and community voices into health research priorities.

Prior to Alberta Innovates, Tim served in senior leadership roles at the Michael Smith Foundation for Health Research, Princess Margaret Hospital, and the BC Cancer Agency. He also built a successful independent consulting practice supporting health research and innovation initiatives nationally.

Tim holds a Master of Health Administration (University of Toronto), a Master of Business Administration (Queen’s University), and is a Certified Professional Accountant (CPA). In 2023, he was recognized as Digital Health Canada’s Digital Health Executive of the Year.
Tim’s work continues to be guided by a commitment to drive transformation that improves lives.

Dr. Sutcliffe is a clinical oncologist, no longer in clinical practice. He graduated from St. Bartholomew’s Hospital, University of London (1970) and trained in internal medicine, scientific research, medical and radiation oncology in the UK, South Africa, US and Canada.

He is President of Two Worlds Cancer Collaboration (2009-to date), a volunteer-based non-profit Society bridging disparities in cancer control between the higher and lesser-resourced worlds. Formerly, he was President and CEO of the Ontario Cancer Institute/ Princess Margaret Hospital (1994-96), the BC Cancer Agency (2000-09), Chair of the Governing Council of the Canadian Strategy for Cancer Control, inaugural vice-chair and past-Chair of its’ federally-funded successor, the Canadian Partnership against Cancer (2007-2012).

Past and current roles include government-funded institutions, non -governmental organizations, private sector companies, charitable foundations and international cancer control networks.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.